MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has joined the Alliance for mRNA Medicines (AMM), as a founding member.

FDA’s new head of device safety held senior role at company troubled by safety warnings

The Food and Drug Administration has tapped Ross Segan, a former device industry exec and Army veteran, to lead its division charged with ensuring medical

September 20, 2024

Hearing Scheduled in Massachusetts for Bills to Legalize Certain Psychedelic Plant Medicines | Psychedelic Spotlight

BOSTON, MASSACHUSETTS – The Massachusetts legislature’s Joint Committee on the Judiciary recently announced that it will hold a hybrid public hearing on Tuesday June 13th from

June 15, 2023

New method traces primed resistance in cancer via sister cells

In many cancers, such as ovarian cancer, each round of chemotherapy kills the majority of cancer cells, while a small population of them survives through

February 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.